Philip Hart, MD
Gastroenterology · Columbus, OHNPI 1295939361
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,289 of the $58,284 with a category attached, or 62.3%. Amgen accounts for 91.8% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $43,632, 6.4 times the $6,813 reported in 2022. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1665.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$54K
- Sagent Pharmaceuticals$5K
- Boston Scientific$189
Across 2 payments — averaging $3562.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sagent Pharmaceuticals$7K
What the payments were for
- Consulting fees$19,21833%
- Speaking & faculty fees$36,28962%
- Travel & lodging$1,9493%
- Food & beverage$8281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $53,532 |
| Sagent Pharmaceuticals | 1 | $4,563 |
| Boston Scientific | 2 | $189 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$34,745
How this compares
$58,284 in reported general payments places this provider in the 90th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 36 | $241,836 |
| Ondansetron OdtOndansetron | 11 | $421 |
| Pantoprazole Sodium | 11 | $84 |
| Omeprazole | 14 | $71 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Columbus
- Tasos ManokasColumbus$411K
- Jeffrey LefkovitzColumbus$164K
- Adam HanjeColumbus$139K
- David LoColumbus$126K
- Shail GovaniColumbus$120K
- William SaltColumbus$87K
- Abdulfatah IssakColumbus$53K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.